About Nyxoah
Nyxoah is a company based in Mont-saint-guibert (Belgium) founded in 2009. Nyxoah has raised $88.73 million across 10 funding rounds from investors including ResMed, Cochlear and European Union. The company has 11 employees as of December 31, 2020. Nyxoah offers products and services including Genio. Nyxoah operates in a competitive market with competitors including Muse, Biotricity, SleepScore Labs, Dreem and Jawbone, among others.
- Headquarter Mont-saint-guibert, Belgium
- Employees 11 as on 31 Dec, 2020
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nyxoah Sa
-
Annual Revenue
$7.45 M (USD)27as on Dec 31, 2018
-
Net Profit
$10.51 M (USD)18as on Dec 31, 2018
-
EBITDA
Not available
-
Total Equity Funding
$88.73 M (USD)
in 10 rounds
-
Latest Funding Round
$26.4 M (USD), Post-IPO
Dec 18, 2025
-
Investors
ResMed
& 7 more
-
Employee Count
11
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nyxoah
Nyxoah offers a comprehensive portfolio of products and services, including Genio.
Treats obstructive sleep apnea via hypoglossal nerve stimulation therapy.
People of Nyxoah
Unlock access to complete
Unlock access to complete
Funding Insights of Nyxoah
Nyxoah has successfully raised a total of $88.73M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $26.4 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nyxoah
Nyxoah has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include ResMed, Cochlear and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Private equity and venture captial firm focused on healthcare sectors
|
Locked | Locked | Locked | |
|
Buyouts are pursued by SRIW as a private equity firm.
|
Locked | Locked | Locked |
Investor details for Nyxoah
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nyxoah
Investment portfolio details for Nyxoah
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nyxoah
Detailed financials for Nyxoah
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nyxoah Comparisons
Peer comparison for Nyxoah
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nyxoah
Nyxoah operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Muse, Biotricity, SleepScore Labs, Dreem and Jawbone, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
EEG-powered headbands for meditation and sleep biofeedback are developed.
|
|
| Locked | Locked | Locked |
Developer of medical remote monitoring solutions that help prevent and manage chronic diseases
|
|
| Locked | Locked | Locked |
Sleep quality is monitored via bedside devices and mobile apps.
|
|
| Locked | Locked | Locked |
Sleep quality is monitored via Dreem's wearable EEG device.
|
|
| Locked | Locked | Locked |
Provider of wearable devices for activity and sleep tracking
|
Detailed competitors of Nyxoah
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nyxoah
Complete news archive for Nyxoah
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nyxoah
Nyxoah was founded in 2009.
Nyxoah is headquartered in Mont-saint-guibert, Belgium.
Olivier Taelman is the current CEO of Nyxoah.
Nyxoah is a funded company, having raised a total of $88.73M across 10 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Nyxoah is 11.
Annual revenue of Nyxoah is $7.45M as on Dec 31, 2018.
Provider of a neurostimulation device for obstructive sleep apnea treatments. The companys product BLAST-OSA (BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea) is used for treating sleep apnea and calculating ODI (Oxygen Desaturation Index) and AHI (Apnea-Hypopnea Index). Its system consists of an implant and disposable patch, which stimulate the nerves of the tongue to make it move, preventing airway obstruction.
Nyxoah's top competitors include Muse, Jawbone and Biotricity.
Nyxoah offers Genio.
Nyxoah has 8 investors. Key investors include ResMed, Cochlear, European Union, EIC Fund, and Gilde Healthcare.